Vitae Biomedical Co., Ltd. participated in Medical Japan Tokyo, one of the largest healthcare exhibitions in Japan, held at Makuhari Messe. The event brought together healthcare professionals, distributors, and industry stakeholders, serving as a key platform for international collaboration and market development.

Selected by the Taipei City Government to join the “Smart Taipei Medical Pavilion,” Vitae Biomedical showcased its non-invasive urine-based lung cancer detection technology alongside leading Taiwanese healthcare innovators. The exhibition highlighted Taiwan’s strengths in integrating medical, technological, and industrial capabilities within the global smart healthcare landscape.

During the event, the company’s diagnostic solution attracted strong interest from medical professionals and industry participants. Discussions were initiated with local medical device distributors, pharmacy channel partners, and healthcare institutions, establishing initial communication channels for future collaboration in the Japanese market.

The company also engaged with Japanese industry media, further increasing visibility and awareness of its technology. The response from professional audiences underscored the potential of non-invasive screening solutions to address existing limitations in early lung cancer detection, particularly in improving accessibility and screening efficiency.

Through participation in Medical Japan Tokyo, Vitae Biomedical has taken a significant step toward entering the Japanese market. By building early-stage relationships across distribution and healthcare networks, the company is laying the groundwork for future clinical collaboration, regulatory alignment, and commercial deployment.